Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
315.5 INR | +2.45% | +3.19% | +26.38% |
07:14am | US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz | MT |
May. 17 | Jefferies Adjusts Biocon’s Price Target to INR230 From INR250, Keeps at Underperform | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.38% | 4.42B | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.96% | 21.97B | |
-5.29% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon's Biologics Arm Completes Integration of Viatris Biosimilar Business in 120 Countries